Table 3.

Multivariable regression analyses for outcomes at 5 years (group A vs group C).

OutcomesStatistic TypesModel 1Model 2Model 3
PE95% CIpPE95% CIpPE95% CIp
Increase in SDIRR0.710.52–0.950.020.720.53–0.980.040.730.54–0.990.04
FlaresRR0.940.82–1.090.430.950.82–1.100.530.940.81–1.080.38
LDA achievement at yr 5OR1.961.18–3.260.0092.091.25–3.520.0051.881.11–3.190.02
Adjusted mean SLEDAI-2K over 5 yrsß0.10−0.19 to 0.400.490.12−0.18 to 0.420.450.11−0.20 to 0.420.49
Cumulative dose of GCS over 5 yrsß−3.46−4.65 to −2.28< 0.0001−3.57−4.77 to −2.37< 0.0001−3.28−4.50 to −2.06< 0.0001
  • Group A: antimalarial agent intake > 60% of time; Group C: non-antimalarial agent intake. Model 1 is the primary analysis; Model 2 is the sensitivity analysis that forced musculoskeletal organ involvement into the model; Model 3 is the sensitivity analysis that forced renal organ involvement into the model. PE: parameter estimates; RR: relative risk from Poisson regression; OR from logistic regression; ß: regression coefficient from linear regression; GCS: glucocorticosteroids; LDA: low disease activity; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000.